Biotech company snaps up US firm in £23m deal
Leeds’ Tissue Regenix Group has acquired a US regenerative medicine business, CellRight, in a £23m ($30m) deal.
Texas-based CellRight specialises on the development and commercialisation of human tissue products, including bone processing and products involved in spine, dental, sports medicine and general surgery. It is registered with the US Food and Drink Administration, and operates from a 13,650 sq ft facility in Universal City.
Tissue Regenix also announced its intention to raise £40m through a placing of 400m shares wi... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
